Compare GSK plc (GSK) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Rigetti Computing Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Rigetti Computing Inc trades at $14.05 (market cap $4.72B). The key difference: GSK plc is far larger — about 19.5× Rigetti Computing Inc's market cap, and GSK plc pays a 3.9% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Rigetti Computing Inc for 35 Days on average.
| GSK | RGTI | |
|---|---|---|
Market Cap | $91.88B | $4.72B |
Volume | 7,730,529 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $61.18 | $56.34 |
52-Week Low | $43.24 | $12.90 |
Typical Hold Time | 93 Days | 35 Days |
Enterprise Value | $111.88B | $4.33B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
RGTI trades at $14.04, down 3.77% today, with a bearish technical signal despite bullish oscillators. The company shows minimal revenue of $7.09M in 2025 with a massive net loss of -$216.21M, resulting in negative profit margins. Analyst consensus is strongly bullish with 6 buy ratings and a $21.67 price target, representing 54% upside. Recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC strategy with partners like HPE.
While analyst optimism and quantum computing potential offer significant upside, RGTI faces substantial execution risks with negative cash flow, high valuation multiples, and intense competition. The stock presents high-risk/high-reward potential for investors willing to tolerate volatility in exchange for quantum computing exposure, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
